Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02164591 · ClinicalTrials.gov registry record

Escalating Temporary Gastric Electrical Stimulation (GES) for Severe Gastroparesis

A clinical trial, sponsored by Indiana University.

Terminated
Registry status
19
Enrollment target

NCT02164591: Clinical Trial study, sponsored by Indiana University.

NCT02164591 is a clinical trial that was terminated before completion, run by Indiana University. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02164591 was terminated before completion, sponsored by Indiana University.

TERMINATED
Registry status
19 participants
Enrollment target

Study Summary

The purpose of this study is to determine the physiologic effects of temporary gastric electrical stimulation in subjects with severe gastroparesis.

Primary Outcome

Review the symptoms before and after the t-GES placements and follow for any improvement

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2013-02
Est. Completion 2019-01
Indiana University

890 total trials

Why NCT02164591 stopped before completion

NCT02164591 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT02164591 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02164591 about?

NCT02164591 is a clinical study titled "Escalating Temporary Gastric Electrical Stimulation (GES) for Severe Gastroparesis". The purpose of this study is to determine the physiologic effects of temporary gastric electrical stimulation in subjects with severe gastroparesis.

What is the current status of trial NCT02164591?

This trial is currently terminated. The enrollment target is 19 participants. The study started on 2013-02. Estimated completion is 2019-01.

Who is sponsoring clinical trial NCT02164591?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02164591, the US trial registry maintained by the National Library of Medicine. NCT02164591 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.